Previous 10 | Next 10 |
Cue Biopharma (NASDAQ: CUE ): Q4 GAAP EPS of -$0.37 in-line. More news on: Cue Biopharma, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Extended cash runway with $33.3 million from at-the-market equity offerings in Q4’19 Focused and effective execution of clinical development of CUE-101 as a Phase 1 monotherapy dose escalation and expansion trial in HNSCC Immuno-STAT™ Platform for autoimmune disease fe...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Today, we will study why Cue Biopharma ( CUE ) is an attractive pick in 2020. Company overview Incorporated in 2014 and headquartered in Cambridge, Massachusetts, Cue Biopharma ( CUE ) is a clinical-stage biopharmaceutical company focused on developing injectable biologics targeting canc...
CAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today it will present at the...
Oppenheimer initiates coverage of Cue Biopharma (NASDAQ: CUE ) with an Outperform rating based on its assessment of the commercial opportunity for CUE-101 in human papillomavirus-driven cancers. More news on: Cue Biopharma, Inc., Healthcare stocks news, , Read more ...
Presentation Provides Update on Immuno-STAT Platform Demonstrating Selective Modulation of Targeted T cells in Preclinical Models CAMBRIDGE, Mass., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel cla...
CAMBRIDGE, Mass., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today Dr. Mary Simcox, vice ...
Acadia Healthcare (NASDAQ: ACHC ) resumed with Equal Weight rating and $36 (11% upside) price target at Stephens. More news on: Acadia Healthcare Company, Inc., BioMarin Pharmaceutical Inc., Blueprint Medicines Corporation, Healthcare stocks news, Stocks on the move, , Read more ...
Over the past few years, raising money to test out ideas that could lead to new drugs had never been easier. Enthusiasm for new drugs that could treat common forms of cancer and rare inherited disorders has driven market caps for these three companies to substantial sums at a very early stage in...
News, Short Squeeze, Breakout and More Instantly...
Prioritizing autoimmune programs aims to focus upon near-term and intermediate value creation potential, while retaining oncology programs as promising clinical data continues to mature - Company anticipates annualized capital and workforce requirements to be reduced by approximately 25...
Overall response rate (ORR) of 46% and 12-month overall survival (OS) of 96% in first line (1L) recurrent/metastatic (R/M) HPV+ head and neck squamous cell carcinoma (HNSCC) treated with CUE-101 and KEYTRUDA ® (pembrolizumab) Median overall survival (mOS) of 20.8 months in second...
BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced that it will participate in two investor confe...